M-A | Heparin full-dose anticoagulation is beneficial for non-critically ill COVID-19 patients

The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies – Lung

Related:

#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?